CCl4mAb, a specific inhibitor of CCN4, reduces NF-κB activity and then decreases the expression of pro-fibrotic factors, such as TGF-β1, in hepatic fibrosis [214]. This evidence concerns the gene NFKB1 and Hepatic fibrosis.